|
|
Article: Relatively poor efficacy will prevent Merck from fully exploiting the fact that at least three fifths of asthmatics suffer concomitant allergic rhinitis.
- Article from:
- M2 Presswire
- Article date:
- January 13, 2004
CopyrightCOPYRIGHT 2004 Normans Media Ltd. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
M2 PRESSWIRE-13 January 2004-Research and Markets: Relatively poor efficacy will prevent Merck from fully exploiting the fact that at least three fifths of asthmatics suffer concomitant allergic rhinitis(C)1994-2004 M2 COMMUNICATIONS LTD
RDATE:01132004
Research and Markets have announced the addition of the `Stakeholder Perspectives: Asthma - Improvements to Combination Inhalers Will Satisfy a Growing Patient Base` report to their offering.
Asthma is a highly prevalent chronic disease that costs at least $13 billion in the US alone each year. In the UK, there are four times as many people with asthma than with diabetes. The patient potential for ...